The results of a small study presented at EAN 2019 suggest that the neurologic syndromes associated with glutamic acid decarboxylase (GAD65) antibodies do improve in the majority of patients following immunotherapy. Antibody titer also decreases in most patients who improve. However, as the researchers from institutes in San Sebastian, Spain, and Rotterdam, the Netherlands, explained, patients do not completely recover.